Fundraising Fox

Quralis

Cambridge, US · Founded 2016 · Delaware corporation · 10 known investors

quralis.com ↗

QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms. The company was founded by neuroscientists from Harvard to translate emerging discoveries about disease pathways into treatment breakthroughs for ALS patients.

BiotechDeep TechMedical Devicesin /quralis1@QurAlisCo

Founders & leadership

KE
Kevin EgganCo-founder
R
RoetCo-founder
W
WoolfCo-founder
LC
Laia Crespo-MartinDirector
SV
Shafique ViraniExecutive Officer
JF
Johannes FruehaufDirector
MH
Michael HuttonDirector
JB
Jason BrownMr. Brown is the Chief Financial Officer of the Issuer.
AW
Anne WhitakerDirector
KR
Kasper RoetDirector, Executive Officer, Promoter
AS
Amy SchulmanDirector
LD
Luc DochezDirector

Investors · 10

Droia VenturesLeuven · $540Kvia Luc Dochez · board
MC Healthcare VenturesCambridge
Mission BiocapitalSan Francisco · $500K
Mitsui Global InvestmentMenlo Park · $500K – $10M
Sanofi VenturesCambridge · $5M
SV Health InvestorsBoston · $1M – $20M
Dolby Family VenturesreportedSan Francisco
InkefreportedAmsterdam
Polaris PartnersreportedBoston · $500K – $5Mvia Amy Schulman · board
SynconareportedLondonvia Roel Bulthuis · board

Reported raises · per SEC filings

Form D private placements
▶$20MraisedSep 2025 · 19 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Laia Crespo-MartinDirector
  • Shafique ViraniExecutive Officer
  • Johannes FruehaufDirector
  • Michael HuttonDirector
  • Jason BrownExecutive Officer
  • Anne WhitakerDirector
  • Kasper RoetDirector, Executive Officer, Promoter
  • Kasper RoetDirector, Executive Officer, Promoter
  • Amy SchulmanDirector
  • Luc DochezDirector
  • Cillian KingDirector
Offering amount
$24.9M
Amount sold
$20M
First sale
Aug 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$60MraisedMar 2023 · 27 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Johannes FruehaufDirector
  • Cillian KingDirector
  • Hagen CramerExecutive Officer
  • Kasper C.D. RoetDirector, Executive Officer, Promoter
  • Chris ThomajanExecutive Officer
  • Laia Crespo-MartinDirector
  • Angela GengeExecutive Officer
  • Julio E. VegaExecutive Officer
  • Daniel ElbaumExecutive Officer
  • Luc DochezDirector
  • Michael HuttonDirector
  • Amy SchulmanDirector
  • Vikas SharmaExecutive Officer
  • Anne WhitakerDirector
Offering amount
$88M
Amount sold
$60M
First sale
Dec 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedSep 2022 · 19 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Vikas SharmaExecutive Officer
  • Roel BulthuisDirector
  • Daniel ElbaumExecutive Officer
  • Angela GengeExecutive Officer
  • Johannes FruehaufDirector
  • Anne WhitakerDirector
  • Michael HuttonDirector
  • Jonathan BehrDirector
  • Chris ThomajanExecutive Officer
  • Luc DochezDirector
  • Kasper C.D. RoetDirector, Executive Officer, Promoter
  • Amy SchulmanDirector
  • Hagen CramerExecutive Officer
Offering amount
$10M
Amount sold
$5M
First sale
Aug 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$33.2MraisedMay 2020 · 25 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Luc DochezDirector
  • Amy SchulmanDirector
  • Jonathan FlemingDirector
  • Chris ThomajanExecutive Officer
  • Kasper C.D. RoetDirector, Executive Officer, Promoter
  • Jonathan BehrDirector
  • Daniel ElbaumExecutive Officer
  • Johannes FruehaufDirector
  • Roel BulthuisDirector
Offering amount
$60M
Amount sold
$33.2M
First sale
May 2020
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news